| Literature DB >> 29568693 |
Keng H Kong1, Hwee L Ng2, Wei Li2, Dora W Ng1, Siang I Tan1, Kay Y Tay2, Wing L Au2, Louis C S Tan2.
Abstract
Introduction: Fatigue is a common and disabling problem in patients with Parkinson's disease (PD), and there is currently no satisfactory treatment. As acupuncture has been reported to be effective in fatigue related to other conditions, we sought to evaluate its efficacy in PD.Entities:
Keywords: Parkinson's disease; acupuncture; fatigue; randomized controlled trial
Mesh:
Year: 2017 PMID: 29568693 PMCID: PMC5853635 DOI: 10.1002/brb3.897
Source DB: PubMed Journal: Brain Behav Impact factor: 2.708
Figure 1Study flowchart and CONSORT diagram
Group demographics and characteristics
| Overall mean ± | Acupuncture mean ± | Sham mean ± |
| |
|---|---|---|---|---|
| Age (years) | 64.6 ± 8.4 | 66.4 ± 6.5 | 62.9 ± 9.7 | .19 |
| Female | 27 (67.5) | 14 (70.0) | 13 (65.0) | .73 |
| Duration of PD (months) | 68.8 ± 45.5 | 87.2 ± 53.2 | 50.1 ± 26.4 |
|
| Levodopa equivalent dosage | 615.2 ± 347.9 | 637.8 ± 394.3 | 592.6 ± 303.1 | .68 |
| MFI – Total | 59.3 ± 12.8 | 61.6 ± 15.1 | 56.6 ± 9.2 | .23 |
| MFI – General Fatigue | 13.4 ± 2.8 | 13.4 ± 2.9 | 14.0 ± 2.7 | .47 |
| UPDRS Motor | 25.4 ± 12.4 | 27.1 ± 13.7 | 23.8 ± 10.9 | 0.39 |
| PDQ‐39 | 31.2 ± 22.6 | 38.4 ± 25.1 | 23.7 ± 17.5 |
|
| ESS | 7.1 ± 4.0 | 7.5 ± 3.8 | 6.7 ± 4.4 | 0.59 |
| GDS | 3.6 ± 2.9 | 4.0 ± 3.3 | 3.3 ± 2.5 | 0.44 |
p ‐ values that are in bold shows statistical significance.
Mean scores of outcome measures at baseline and on follow up and between‐group differences
| Acupuncture |
| Sham |
|
| |
|---|---|---|---|---|---|
| MFI – GENERAL FATIGUE | |||||
| Baseline | 13.4 ± 2.9 | 14.0 ± 2.7 | |||
| Week 5 | 10.4 ± 3.3 | .001 | 9.3 ± 2.9 | <.001 | .09 |
| Week 9 | 10.6 ± 3.37 | .006 | 10.5 ± 3.2 | <.001 | .60 |
| MFI – Total | |||||
| Baseline | 61.6 ± 15.1 | 56.6 ± 9.2 | |||
| Week 5 | 52.5 ± 15.5 | <.001 | 47.2 ± 10.6 | .003 | .48 |
| Week 9 | 52.7 ± 15.1 | <.001 | 48.5 ± 8.0 | .006 | .21 |
| UPDRS motor | |||||
| Baseline | 27.1 ± 13.7 | 23.8 ± 10.6 | |||
| Week 5 | 22.5 ± 12.1 | .009 | 23.7 ± 10.9 | .74 | .14 |
| Week 9 | 24.8 ± 16.3 | .025 | 23.8 ± 10.6 | .38 | .94 |
| PDQ‐39 | |||||
| Baseline | 38.4 ± 25.1 | 23.7 ± 17.5 | |||
| Week 5 | 30.3 ± 25.5 | .12 | 19.5 ± 15.2 | .07 | .74 |
| Week 9 | 34.3 ± 25.8 | .19 | 18.6 ± 16.0 | .07 | .21 |
| ESS | |||||
| Baseline | 7.5 ± 3.8 | 6.7 ± 4.4 | |||
| Week 5 | 5.8 ± 4.3 | .11 | 5.2 ± 4.6 | .13 | .90 |
| Week 9 | 5.5 ± 3.6 | .09 | 5.2 ± 3.6 | .17 | .94 |
| GDS | |||||
| Baseline | 4.0 ± 3.3 | 3.3 ± 2.5 | |||
| Week 5 | 3.2 ± 2.7 | .26 | 2.8 ± 2.3 | .23 | .71 |
| Week 9 | 3.8 ± 2.8 | .96 | 2.3 ± 2.3 | .17 | .09 |